Document and Entity Information |
May 29, 2025 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | FATE THERAPEUTICS INC |
| Amendment Flag | true |
| Entity Central Index Key | 0001434316 |
| Document Type | 8-K/A |
| Document Period End Date | May 29, 2025 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-36076 |
| Entity Tax Identification Number | 65-1311552 |
| Entity Address, Address Line One | 12278 Scripps Summit Dr. |
| Entity Address, City or Town | San Diego |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92131 |
| City Area Code | 858 |
| Local Phone Number | 875-1800 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value per share |
| Trading Symbol | FATE |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Current Report on Form 8-K/A (this “Amended Form 8-K”) amends Item 5.07 of the Current Report on Form 8-K filed by Fate Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission on May 30, 2025 (the “Original Form 8-K”). Item 5.07 of the Original Form 8-K reported the results of the matters submitted for stockholder action at the Company’s 2025 annual meeting of stockholders held on May 29, 2025 (the “2025 Annual Meeting”). The sole purpose of this Amended Form 8-K is to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company’s decision as to the frequency of future non-binding advisory votes to approve the compensation of the Company’s named executive officers. Except as set forth herein, no other changes have been made to the Original Form 8-K. |